NIH NOTICES

Extension of Certain Flexibilities for Prospective Basic Experimental Studies With Human Participants (NOT-OD-19-126)
National Institutes of Health

Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research (NOT-OD-19-128)
National Institutes of Health

Notice of Clarification to PAR-18-841, "Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)" (NOT-CA-19-064)
National Cancer Institute

Notice of Intent to Publish the Reissuance of RFA-CA-18-026, "Improving the Reach and Quality of Cancer Care in Rural Populations (R01 Clinical Trial Required)" (NOT-CA-19-063)
National Cancer Institute

National Cancer Institute

Correction to RFA-CA-19-034 "Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities". (NOT-CA-19-061)
National Cancer Institute

Notice of Change to the Award Budget for PAR-18-303 Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44). (NOT-CA-19-062)
National Cancer Institute

Reminders of NIH Policies on Other Support and on Policies related to Financial Conflicts of Interest and Foreign Components (NOT-OD-19-114)
National Institutes of Health

Pre-Application Webinars for Participant Engagement and Cancer Genome Sequencing (PE-CGS): Funding Opportunities (RFA-CA-19-045, RFA-CA-19-046) (NOT-CA-19-065)
National Cancer Institute

Notice of Clarification to Eligibility Information in PAR-19-349 "NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed)" (NOT-CA-19-069)
National Cancer Institute

Correction to RFA-CA-19-045 "Participant Engagement and Cancer Genome Sequencing (PE-CGS) (U2C Clinical Trial Optional)" (NOT-CA-19-070)
National Cancer Institute

Pre-Application Webinar for RFA-CA-19-033 "Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required)" (NOT-CA-19-068)
National Cancer Institute
SEPTEMBER DEADLINES

Foundation and Other Sources

Concern Foundation
Conquer Cancer Now Award
Letter of Intent Deadline: 9/12/2019
Full Application Deadline: 12/05/2019
https://www.concernfoundation.org/apply-for-grant.html
About: The Conquer Cancer Now Award is a $60,000 grant given to young and innovative cancer researchers focused on cancer genetics, cancer biology and cancer immunology. Priority is given to proposals from independent investigators who have yet to obtain significant funding for their work.
Period of Support: 2 years
Funds/Direct Costs: $60,000 total costs per year
Program Contact: Seunga Yu
(310) 360-6100
info@concernfoundation.org

Hope Funds for Cancer Research
Postdoctoral Fellowship Award
Deadline: 9/18/2019
http://www.hope-funds.org/grants/eligibility-and-application/
About: Hope Funds for Cancer Research is offering fellowships to postdoctoral scientists who propose to work on highly innovative research projects that challenge the traditional paradigms of understanding the causes, mechanisms, progression, disease markers or risk factors of the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, bone and ovarian cancers; and rare leukemias, lymphomas and MDS. The Trustees of the Hope Funds believe that funding research that could lead to breakthroughs in these areas and increase life expectancy in these types of cancers is at the core of its mission.
Period of Support: 3 years
Funds/Direct Costs: $50,000 (Year 1), $52,000 (Year 2), $54,000 (Year 3) direct costs per year
Program Contact: Hope Funds for Cancer Research
(401) 847-3286
grants@hope-funds.org

Susan G. Komen Foundation
Deadline: 9/25/2019
https://ww5.komen.org/ResearchGrants/FundingOpportunities.html
About: Komen is excited to announce a new funding opportunity for researchers to use a truly unique resource: The Susan G. Komen® Tissue Bank at the IU Simon Cancer Center (Komen Tissue Bank, or KTB), the first and only biorepository in the world containing breast tissue and blood products from donors that show no evidence of breast cancer at the time of donation. Since 2007, over 8,000 women have donated their blood and/or tissue to help the research community. To leverage this valuable resource, we are seeking the best ideas in innovative research proposals to move the field of breast cancer forward.
Period of Support: Up to 2 years
Funds/Direct Costs: $200,000 total costs for up to 2 years.
Program Contact: Susan G. Komen
(877) 465-6636
helpline@komen.org

Program Announcements (PA)

Multiple Institutes, including the National Cancer Institute Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)
Deadline: 9/25/2019
About: The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Susan E. Lim
(240) 276-5472
lims@mail.nih.gov

National Cancer Institute
Cancer Research Education Grants Program - Curriculum or Methods Development (R25)
Deadline: 09/25/2019
About: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Curriculum or Methods Development.
**Period of Support**: Up to 2 years  
**Funds/Direct Costs**: $150,000 direct costs per year  
**Program Contact**: Jeannette Korczak  
(240) 276-5630  
korczakj@mail.nih.gov

---

**National Cancer Institute**  
**Perception and Cognition Research to Inform Cancer Image Interpretation (R21)**  
**Deadline**: 9/26/2019  
**About**: The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.  
**Period of Support**: Up to 2 years  
**Funds/Direct Costs**: $275,000 direct costs for entire period of support  
**Program Contact**: Todd Horowitz  
(240) 276-6963  
todd.horowitz@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Perception and Cognition Research to Inform Cancer Image Interpretation (R01)**  
**Deadline**: 9/26/2019  
**About**: The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.  
**Period of Support**: Up to 5 years  
**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact**: Todd Horowitz  
(240) 276-6963  
todd.horowitz@nih.gov

---

**National Cancer Institute**  
**Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)**  
**Deadline**: 9/30/2019  
**About**: The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae.  
**Period of Support**: Up to 5 years  
**Funds/Direct Costs**: Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact**: Kelly Filipski  
(240) 276-6841  
flipskikk@mail.nih.gov

---

**National Cancer Institute**  
**Cancer Research Education Grants Program - Research Experiences (R25)**  
**Deadline**: 09/25/2019  
**About**: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. This FOA will support creative educational activities with a primary focus on Research Experiences.  
**Period of Support**: Up to 5 years  
**Funds/Direct Costs**: $300,000 direct costs per year  
**Program Contact**: Jeannette Korczak  
(240) 276-5630  
korczakj@mail.nih.gov
National Cancer Institute

**National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)**

*Deadline:* 9/25/2019


**About:** With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Referral Officer
(240) 276-6390
ncirefof@dea.nci.nih.gov

---

National Cancer Institute

**Administrative Supplements to Support Cancer Disparity Collaborative Research**

*Deadline:* 09/10/2019


**About:** The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** $150,000 direct costs per year

**Program Contact:** Liz Perruccio
(240) 276-6178
liz.perruccio@nih.gov

---

National Cancer Institute

**Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01)**

*Deadline:* 09/12/2019


**About:** This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are limited to $500,000 in direct costs per year

**Program Contact:** Robert J. Nordstrom
(240) 276-5934
nordstrr@mail.nih.gov

---

National Cancer Institute

**Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)**

*Deadline:* 9/27/2019


**About:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Direct costs are limited to $300,000 per year.

**Program Contact:** Tony Dickherber
(301) 547-9980
dickherberaj@mail.nih.gov

---

National Cancer Institute

**Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)**

*Deadline:* 9/27/2019


**About:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Direct costs are limited to $300,000 per year.

**Program Contact:** Tony Dickherber
(301) 547-9980
dickherberaj@mail.nih.gov

---

Request for Applications (RFA)

National Cancer Institute

**Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)**

*Deadline:* 9/27/2019


**About:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Direct costs are limited to $300,000 per year.

**Program Contact:** Tony Dickherber
(301) 547-9980
dickherberaj@mail.nih.gov
National Cancer Institute  
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21)  
**Deadline:** 9/27/2019  
**About:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens.  
**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.  
**Program Contact:** Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov

---

National Cancer Institute  
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)  
**Deadline:** 9/27/2019  
**About:** This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.  
**Period of Support:** Up to 3 years  
**Funds/Direct Costs:** Direct costs are limited to $400,000 over a 3-year period, with no more than $200,000 in direct costs allowed in any single year.  
**Program Contact:** Tony Dickherber  
(301) 547-9980  
dickherberaj@mail.nih.gov

---

Intramural Funding Opportunities

**Massey Cancer Center, Pauley Heart Center Pilot Project Opportunity in Cardio-Oncology**  
**Deadline:** 9/19/2019  
For submission guidelines, email Farah Mirza  
**About:** Together, the Pauley Heart Center and Massey Cancer Center are offering a one-time funding opportunity for up to $50,000 for a pilot project grant to stimulate NEW collaborative research initiatives that will take on a life of their own after the funding is spent. The intent is to support critical searching experiments that will lay the groundwork needed for grant applications to external peer-reviewed funding organizations. The topic area for this submission will include the field of Cardio-Oncology and is open to address issues related to immunology, obesity, inflammation and metabolism, biomedical engineering, imaging, exercise physiology, behavioral science, or population based sciences.  
**Period of Support:** 1 year  
**Funds/Direct Costs:** Up to $50,000  
**Program Contact:** Farah Mirza  
(804) 628-1750  
fmirza@vcu.edu

---

**OCTOBER/NOVEMBER DEADLINES**

Foundation and Other Sources

**The Mike Slive Foundation Pilot Grant Program in Prostate Cancer Research**  
**Deadline:** 10/1/2019  
[https://mikeslivefoundation.org/prostate-cancer/research-grants/](https://mikeslivefoundation.org/prostate-cancer/research-grants/)  
**About:** This opportunity is open to all faculty and clinicians interested in innovative prostate cancer research. The purpose is to support highly meritorious scientific research in prostate cancer. Applications in all areas of research are encouraged. This award is intended to "seed" nascent prostate cancer projects that will become competitive for extramural funding with the data generated as a result of receiving pilot funds. Please email a 3 page description of the research proposed, your NIH biosketch or CV, and a brief layman's overview (300 words) to emily@mikeslivefoundation.org  
**Period of Support:** 1 year  
**Funds/Direct Costs:** $50,000 or more for a 12 month period beginning January 1, 2020  
**Program Contact:** Emily Capilouto  
(205) 903-4324  
emily@mikeslivefoundation.org

---

**American Cancer Society Research Scholar Grants**  
**Deadline:** 10/15/2019  
[https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant/grant-types/research-scholar-grants.html](https://www.cancer.org/research/we-fund-cancer-research/apply-research-grant/grant-types/research-scholar-grants.html)  
**About:** The Research Scholar Grant (RSG) supports investigator-initiated projects across the cancer research...
continuum. Independent investigators in the first 6 years of an independent research career of faculty appointment are eligible to apply. Eligibility is extended for 8 years for clinician scientists who remain active in clinical care.

**Period of Support:** Up to 4 years
**Funds/Direct Costs:** Up to $165,000 direct costs per year
**Program Contact:** ACS
(404) 329-7558
grants@cancer.org

**American Lung Association**
**Lung Cancer Discovery Award**
**Letter of Intent Deadline:** 10/03/2019
**Full Application Deadline:** 1/23/2020

**About:** The objective of the Lung Cancer Discovery Award is to support independent investigators conducting clinical, laboratory, epidemiological or any groundbreaking project aimed at revolutionizing our current understanding of lung cancer and improving diagnostic, clinical and treatment methods

**Period of Support:** 2 years
**Funds/Direct Costs:** $100,000 per year
**Program Contact:** ALA
research@lung.org

**Cancer Research Institute**
**Clinic & Laboratory Integration Program (CLIP)**
**Deadline:** 11/1/2019
https://www.cancerresearch.org/scientists/fellowships-grants/translational-research-grants

**About:** The Cancer Research Institute funds research aimed at furthering the development immunological approaches to the diagnosis, treatment, and prevention of cancer. The CLIP Grants are offered to qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The program supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic.

**Period of Support:** 2 years
**Funds/Direct Costs:** Up to $100,000 direct costs per year
**Program Contact:** CRI
(212) 688-7515
grants@cancerresearch.org

**The Skin Cancer Foundation**
**Research Grants Award**
**Deadline:** 11/1/2019
https://www.skincancer.org/for-medical-professionals/research-grants

**About:** The Skin Cancer Foundation is now accepting applications for our 2020 Research Grants to support pilot research projects related to skin cancer. The Foundation funds basic research and clinical studies that address improved methods of prevention, detection and treatment of skin cancer.

**Period of Support:** 1 year
**Funds/Direct Costs:** Up to $50,000 direct costs
**Program Contact:** The Skin Cancer Foundation
(212) 725-5176
research@skincancer.org

**Alex’s Lemonade Stand Foundation (ALSF)**
**Innovation Grant**
**Letter of Intent Deadline:** 11/04/2019
**Full Application Deadline:** 4/05/2020
https://www.alexslemonade.org/grants/program-areas/accelerator-programs

**About:** Innovation Grants are designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers. Proposals should have clinical translation in view. This may represent a change in research direction and/or an innovative new idea that moves away from an investigator’s prior research but for which a strong case is made for the potential impact on childhood cancers.

**Period of Support:** 2 years
**Funds/Direct Costs:** $125,000 direct costs per year.
**Program Contact:** ALS Foundation
(866) 333-1213
grants@alexslemonade.org

**Program Announcements (PA)**

**Multiple Institutes, including the National Cancer Institute**
**Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01)**
**Deadline:** 10/05/2019

**About:** This funding opportunity announcement (FOA) encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes. The goal of this initiative is to address key scientific questions relevant to cancer epidemiology by supporting the analysis of existing genetic or genomic datasets, possibly in combination with environmental, outcomes, behavioral, lifestyle, and molecular profiles data.

**Period of Support:** Up to 5 years
**Funds/Direct Costs:** The budget is limited to $350,000 Direct Costs per year
**Program Contact:** Carol Perry
National Cancer Institute
Leveraging Population-based Cancer Registry Data to Study Health Disparities (R21)
**Deadline:** 10/16/2019

**About:** The goal of this Funding Opportunity Announcement (FOA) is to efficiently use the existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000

**Program Contact:** Kathleen Cronin  
(240) 276-6836  
cronink@mail.nih.gov

---

National Cancer Institute
Integration of Individual Residential Histories into Cancer Research (R01)
**Deadline:** 10/5/2019

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Zaria Tatalovich  
(240) 276-6976  
tatalovichzp@mail.nih.gov

---

National Cancer Institute
The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21)
**Deadline:** 10/16/2019

**About:** The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** $275,000 direct costs for entire period of support

**Program Contact:** Konstantin Salnikow  
(240) 276-6230  
salnikok@mail.nih.gov

---

Multiple Institutes, including the National Cancer Institute
Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed)
**Deadline:** 10/16/2019

**About:** This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Application budgets are limited to $275,000 in direct costs per year

**Program Contact:** Long Nguyen  
(240) 276-5807  
long.nguyen@nih.gov

---

Multiple Institutes, including the National Cancer Institute
Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01  Clinical Trial Optional)
**Deadline:** 10/05/2019

**About:** This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Erica S. Breslau  
(240) 276-6773  
breslaue@mail.nih.gov

---

Multiple Institutes, including the National Cancer Institute
Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01)
**Deadline:** 10/5/2019

**Program Contact:** Konstantin Salnikow  
(240) 276-6230  
salnikok@mail.nih.gov

---

About: The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults.

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Erica Breslau
(240) 276-6773
breslaue@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers (R21 Clinical Trial Optional)
Deadline: 10/5/2019

About: This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Period of Support: Up to 2 years

Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.

Program Contact: Michelle Mollica
(240) 276-7621
michelle.mollica@nih.gov

National Cancer Institute
Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R21 Clinical Trial Optional)
Deadline: 10/16/2019

About: The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.

Period of Support: Up to 2 years

Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.

Program Contact: Wendy Nelson
(240) 276-6971
nelsonw@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21 Clinical Trial Optional)
Deadline: 10/16/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults.

Period of Support: Up to 2 years

Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.

Program Contact: Erica S. Breslau
(240) 276-6773
breslaue@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)
Deadline: 10/05/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models.

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Gurvaneet S. Randhawa
(240) 276-6940
gurvaneet.randhawa@nih.gov

Using Information Technology to Support Systematic Screening and Treatment of Depression in Oncology Practices (R01 Clinical Trial Optional)
Deadline: 10/05/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; test the effectiveness of these new delivery models, and their components, in a variety of oncology practice settings, especially those serving under-served populations; and evaluate the sustainability and scalability of these new delivery models.

Period of Support: Up to 5 years

Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.

Program Contact: Gurvaneet S. Randhawa
(240) 276-6940
gurvaneet.randhawa@nih.gov

End-of-Life and Palliative Care Health Literacy: Improving Outcomes in Serious, Advanced Illness (R01 Clinical Trial Optional)
Deadline: 10/05/2019
National Cancer Institute
Early-life Factors and Cancer Development Later in Life (R03)
Deadline: 10/16/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors (maternal-paternal, in utero, birth and infancy, puberty, adolescence, and young adult years) in cancer development later in life.
Period of Support: Up to 2 years
Funds/Direct Costs: $100,000 direct costs per year
Program Contact: Somdat Mahabir
(240) 276-6941
mahabir@mail.nih.gov

National Cancer Institute
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
Deadline: 10/05/2019
About: Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are limited to $499,999 (maximum) in direct costs per year
Program Contact: Anne Menkens
(240) 276-6510
menkensa@mail.nih.gov

National Cancer Institute
Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 - Clinical Trial Not Allowed)
Deadline: 10/5/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Somdat Mahabir
(240) 276-6941
mahabir@mail.nih.gov
need to reflect the actual needs of the proposed project.

**Program Contact:** Tram Kim Lam  
(240) 276-6967  
Tram.Lam@nih.gov

**Multiple Institutes, including the National Cancer Institute**  
**Exploratory/Developmental Clinical Research Grants in Obesity (R21 Clinical Trial Optional)**  
**Deadline:** 10/16/2019  

**About:** This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Application budgets are limited to $275,000 in direct costs per year.

**Program Contact:** Tanya Agurs-Collins  
(240) 276-6956  
collinsta@mail.nih.gov

**Multiple Institutes, including the National Cancer Institute**  
**Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R01 Clinical Trial Optional)**  
**Deadline:** 10/05/2019  

**About:** This FOA calls for research grant applications that address patient adherence to treatment and prevention regimens to promote health outcomes. Applications may address healthcare regimen initiation, implementation, and/or persistence by patients.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Gabriela Riscuta  
(240) 276-7118  
gabriela.riscuta@nih.gov

**Multiple Institutes, including the National Cancer Institute**  
**Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations**  
**Deadline:** 10/5/2019  

**About:** This Funding Opportunity Announcement (FOA) invites applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.
Multiple Institutes, including the National Cancer Institute
Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)
Deadline: 10/16/2019
About: The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience.
Period of Support: 2 years
Funds/Direct Costs: $275,000 direct costs for entire period of support
Program Contact: Erica Breslau
(240) 276-6773
breslaue@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)
Deadline: 10/5/2019
About: The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on the biobehavioral basis of chronic pain. The focus encompasses the individual phenotype, genotype, and other omic-type assessments and the associated sensory and emotional components that underpin the individual's chronic pain experience.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Ann O'Mara
(240) 276-7050
omaraa@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01)
Deadline: 10/5/2019
About: The purpose of the Funding Opportunity Announcement is to encourage grant applications from the scientific community on applying a biopsychosocial perspective to self-management of chronic pain.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Ann O'Mara
(240) 276-7050
omaraa@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R21)
Deadline: 10/16/2019
About: This Funding Opportunity Announcement encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes.
Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the entire project period may not exceed $275,000.
Program Contact: Nonniekaye Shelburne
(240) 276-6897
nshelburne@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed)
Deadline: 10/12/2019
About: The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08)
program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Award budgets are composed of salary and other program-related expenses, as described in announcement.

**Program Contact:** Susan Lim  
(240) 276-5588  
lims@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)**  
**Deadline:** 10/05/2019  

**About:** The purpose of this FOA is to encourage mechanistic research to investigate the impact of sleep disturbances on pain. The mechanisms and processes underlying the contribution of sleep and sleep disturbances to pain perception and the development and maintenance of chronic pain may be very broad. This FOA encourages interdisciplinary research collaborations by experts from multiple fields—neuroscientists, psychologists, endocrinologists, immunologists, geneticists, pharmacologists, chemists, physicists, behavioral scientists, clinicians, caregivers, and others in relevant fields of inquiry. Applications proposing to study the impact of pain on sleep will be considered low priority and are unlikely to be funded under this FOA.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Kathleen Cronin  
(240) 276-6836  
cronink@mail.nih.gov

---

**National Cancer Institute**  
**Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)**  
**Deadline:** 10/05/2019  

**About:** The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. This FOA encourages the design of research projects that utilize the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits; 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.

**Period of Support:** Up to 4 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Sundar Venkatachalam  
(240) 276-7304  
sundarv@nih.gov
Multiple Institutes, including the National Cancer Institute
Assay development and screening for discovery of chemical probes or therapeutic agents (R01)
Deadline: 10/5/2019

About: Through this funding opportunity announcement (FOA), NIH wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.

Period of Support: Up to 4 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Suzanne Forry
(240) 276-5922
forryscs@mail.nih.gov

National Cancer Institute
Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required)
Deadline: 10/11/2019

About: This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools.

Period of Support: Up to 3 years
Funds/Direct Costs: Application budgets are limited to $500,000 in direct costs per year.
Program Contact: Lori A. Henderson
(240) 276-5930
hendersonlori@mail.nih.gov

National Cancer Institute
NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional)
Deadline: 10/25/2019

About: This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Period of Support: Up to 2 years
Funds/Direct Costs: A budget for direct costs of up to $50,000 per year may be requested.
Program Contact: Crystal Wolfrey
(240) 276-6277
wolfreycc@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Tobacco Use and HIV in Low and Middle Income Countries (R01 Clinical Trial Optional)
Deadline: 11/1/2019

About: The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.

Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Mark Parascandola
(240) 276-6871
Mark.Parascandola@nih.gov

National Cancer Institute
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
Deadline: 10/8/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to support the validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control.

Period of Support: Up to 3 years
Funds/Direct Costs: Applicants may request up to $275,000 direct costs for the entire UH2 phase with no more than $200,000 requested in any one year and up to $250,000 direct costs for the UH3 phase per year.
Program Contact: Tracy G. Lively
(240) 276-5944
livelyt@mail.nih.gov
National Cancer Institute
NCI Transition Career Development Award to Promote Diversity (K22 No Independent Clinical Trials)
Deadline: 10/12/2019
About: The purpose of the NCI Transition Career Development Award to Promote Diversity is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.
Period of Support: Up to 3 years
Funds/Direct Costs: Award budgets are composed of salary and other program-related expenses, as described in announcement.
Program Contact: Abigail Soyombo
(240) 276-6553
Abigail.Soyombo@nih.gov

National Cancer Institute
The NCI Transition Career Development Award (K22 Clinical Trial Not Allowed)
Deadline: 11/12/2019
About: This Funding Opportunity Announcement (FOA) supports an NCI program that facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions.
Period of Support: Up to 3 years
Funds/Direct Costs: Application budgets are composed of salary and other program-related expenses as described in announcement.
Program Contact: Sonia Jakowlew
(240) 276-5630
jakowles@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Advancing the Science of Geriatric Palliative Care (R21 - Clinical Trial Optional)
Deadline: 10/16/2019
About: This Funding Opportunity Announcement (FOA) encourages exploratory or developmental research grant applications to develop new tools, methods, and models focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings.
Period of Support: Up to 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000.
Program Contact: Ann M. O'Mara
(240) 276-7050
omaraa@mail.nih.gov

Multiple Institutes, including the National Cancer Institute
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
Deadline: 10/5/2019
About: The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in basic research to understand disease, or in applied research to assess risk, detect, prevent, diagnose, treat, and/or manage disease.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Miguel R. Ossandon
(240) 276-5714
ossandom@mail.nih.gov

National Cancer Institute
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
Deadline: 10/5/2019
About: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health.
Period of Support: Up to 5 years
Funds/Direct Costs: Application budgets are not limited but need to reflect the actual needs of the proposed project.
Program Contact: Brandy Heckman-Stoddard
(240) 276-7048
heckmanbm@mail.nih.gov
National Cancer Institute
National Cancer Institute’s Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)  
**Deadline:** 10/5/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute’s (NCI) Division of Cancer Treatment and Diagnosis (DCTD).  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are limited to less than $500,000 in direct costs per year  
**Program Contact:** Lori A. Henderson  
(240) 276-5930  
hendersonlori@mail.nih.gov

National Cancer Institute
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01)  
**Deadline:** 10/5/2019  
**About:** Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** $499,999 direct costs per year  
**Program Contact:** Anne Menkens  
(240) 276-6510  
menkensa@mail.nih.gov

National Cancer Institute
Basic Research in Cancer Health Disparities (R01)  
**Deadline:** 11/19/19  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Jennifer Isaacs  
(240) 276-6251  
jennifer.isaacs@nih.gov

National Cancer Institute
U.S. Tobacco Control Policies to Reduce Health Disparities (R21)  
**Deadline:** 10/11/2019  
**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Bob Vollinger  
(240) 276-6919  
bob.vollinger@nih.gov

National Cancer Institute
Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)  
**Deadline:** 10/11/2019  
**About:** This Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic
affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Rebecca Ferrer  
(240) 276-5075  
ferrerra@mail.nih.gov

---

**National Cancer Institute**  
**Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21)**  
**Deadline:** 11/19/2019  

**About:** This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible junior investigators and Early Stage Investigators from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences.  

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Abigail Soyombo  
(240) 276-6553  
abigail.soyombo@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Precision Imaging of Oral Lesions (R01 - Clinical Trial Not Allowed)**  
**Deadline:** 10/5/2019  

**About:** The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx.  

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Shane Woodward  
(240) 276-6303  
woodwars@mail.nih.gov

---

**National Cancer Institute**  
**Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)**  
**Deadline:** 11/19/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials.  

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets for direct costs up to $500,000 per year may be requested.  
**Program Contact:** Nancy Boudreau  
(240) 276-6702  
nancy.boudreau@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Diet and Physical Activity Assessment Methodology (R21)**  
**Deadline:** 10/5/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science (BDS). This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles.  

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Geraldina Dominguez  
(301) 496-3204  
domingug@mail.nih.gov
Clinical Trial Not Allowed)

**Deadline:** 10/16/2019

**About:** This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Direct costs are limited to $275,000 per year

**Program Contact:** Carol Perry
(240) 276-6282
perryc@nci.nih.gov

---

**National Cancer Institute**
**Modular R01s in Cancer Control and Population Sciences (R01)**

**Deadline:** 11/7/2019

**About:** This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** $250,000 direct costs per year

**Program Contact:** Scott Rogers
(240) 276-6932
rogerssc@mail.nih.gov

---

**National Cancer Institute**
**Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01 Clinical Trial Optional)**

**Deadline:** 10/05/2019

**About:** This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Frank Perna
(240) 276-6782
pernafm@mail.nih.gov

---

**National Cancer Institute**
**Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed)**

**Deadline:** 11/13/2019

**About:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers (or Cancer Centers with highly integrated cancer research programs). This FOA is designed to facilitate the planning and execution of focused collaborations in cancer-related research, research experience, and research education.

**Period of Support:** Up to 4 years
**Funds/Direct Costs:** The combined budget of direct costs for ISUPS and CC cannot exceed $375,000 per year.

**Program Contact:** Behrous Davani  
(240) 276-6098  
behrous.davani@nih.gov

---

**National Cancer Institute**  
**Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)**  
**Deadline:** 11/7/2019  
**About:** This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as "liquid biopsies."  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets limited to $250,000 direct costs per year  
**Program Contact:** Abhi Rao  
(240) 276-5715  
abhi.rao@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21)**  
**Deadline:** 10/16/2019  
**About:** The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** $275,000 direct costs for entire period of support  
**Program Contact:** Karen Kehl  
(301) 594-8010  
kehlka@nih.gov

---

**National Cancer Institute**  
**Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)**  
**Deadline:** 10/5/2019  
**About:** This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are limited to $400,000 Direct Costs per year  
**Program Contact:** Nastaran Zahir  
(240) 276-7610  
nas.zahir@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (R01)**  
**Deadline:** 10/5/2019  
**About:** The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12–24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Lynn Adams  
(301) 594-8911  
lynn.adams@nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)**  
**Deadline:** 10/16/2019  
**About:** The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care
delivery, or accessibility.

**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** Application budgets are limited to $275,000 in direct costs per year  
**Program Contact:** Miguel R. Ossandon  
(240) 276-5714  
ossandom@mail.nih.gov

---

**National Cancer Institute**  
**Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)**  
**Deadline:** 10/16/2019  
**About:** The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of Exploratory/Developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.  
**Program Contact:** Miguel R. Ossandon  
(240) 276-5714  
ossandom@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**  
**Accelerating the Pace of Child Health Research Using Existing Data from the Adolescent Brain Cognitive Development (ABCD) Study (R21-Clinical Trial Not Allowed)**  
**Deadline:** 10/16/2019  
**About:** This FOA will support activities proposing to conduct analyses of existing ABCD Study data to accelerate the pace of research on child health and development, including: cross-sectional and/or longitudinal analyses; development of new or advanced statistical methods; and/or integration of multiple data sets with common data elements. Existing data provide unique opportunities to answer novel research questions in a cost-effective way. We also strongly encourage inclusion of statisticians, computational neuroscientists, and interdisciplinary teams to address novel research questions using these data.  
**Period of Support:** Up to 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.  
**Program Contact:** Crystal Wolfrey  
(240) 276-6277  
wolfreyc@mail.nih.gov

---

**National Cancer Institute**  
**Biology of Bladder Cancer (R01 Clinical Trial Optional)**  
**Deadline:** 10/05/2019  
**About:** This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.  
**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.  
**Program Contact:** Ron Johnson  
(240) 276-6250  
rjohnso2@mail.nih.gov

---

**National Cancer Institute**  
**Microbial-based Cancer Therapy -Bugs as Drugs (R01 Clinical Trial Not Allowed)**  
**Deadline:** 10/05/2019  
**About:** The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for
conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaeabacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Avi Rasooly  
(240) 276-6196  
rasoolya@mail.nih.gov

---

**National Cancer Institute**

**Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)**

**Deadline:** 10/16/2019  

**About:** The overall purpose of this funding opportunity announcement (FOA) is to stimulate exploratory development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. The FOA also aims to support research into the use of microorganisms for cancer treatment and to complement or synergize with current therapies.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Young S. Kim  
(240) 276-7115  
yk47s@nih.gov

---

**National Cancer Institute**

**Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Optional)**

**Deadline:** 11/6/2019  

**About:** The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Wendy Wang  
(240) 276-7117  
wangw@mail.nih.gov
**Multiple Institutes, including the National Cancer Institute**

**Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)**

**Deadline:** 10/5/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Crystal Wolfrey  
(301) 496-8634  
wolfreyc@mail.nih.gov

---

**National Cancer Institute**

**Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)**

**Deadline:** 10/08/2019  

**About:** This funding opportunity announcement (FOA) encourages the submission of exploratory/developmental research grant (R21) applications for cancer epidemiologic research. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance population-based cancer research, such as improving data collection methods, developing and validating methods of exposures and biological effects, such as epigenetics and metabolomics, and their application in population-based research, functional assessment of genetic variants, and assessing recruitment methods for understudied populations.

**Period of Support:** 2 years  
**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Mukesh Verma  
(240) 276-6889  
vermam@mail.nih.gov

---

**National Cancer Institute**

**Provocative Questions (PQs) in Multiple Myeloma**

**Deadline:** 11/15/2019  

**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support new research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in multiple myeloma disparities research identified by the National Cancer Institute (NCI) as the NCI’s Multiple Myeloma and Disparities Provocative Questions (MMD PQs).

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Amy Kennedy  
(240) 781-3335  
amy.kennedy@nih.gov

---

**National Cancer Institute**

**Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)**

**Deadline:** 11/15/2019  

**About:** The National Cancer Institute’s (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

**Period of Support:** Up to 5 years  
**Funds/Direct Costs:** Application budgets are limited to $400,000 in direct costs per year.

**Program Contact:** Shannon Hughes  
(240) 276-6224  
shannon.hughes@nih.gov

---

**National Cancer Institute**

**NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed)**

**Deadline:** 10/18/2019  

**About:** The Research Specialist Award is designed to encourage the development of stable research career
opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** See announcement for details.

**Program Contact:** Christine Siemon  
(240) 276-6180  
siemonc@mail.nih.gov

---

### National Cancer Institute

**Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)**

**Deadline:** 10/16/2019  

**About:** The purpose of this FOA is to provide support for the development of innovative interventions that improve cancer-related health behaviors in a variety of settings (e.g., families, communities, and health care delivery settings) across diverse racial/ethnic populations. The aim is to address one or more cancer-related behavioral risk factors to reduce cancer risk and disease burden.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Tanya Agurs-Collins  
(240) 276-6956  
collinsta@mail.nih.gov

---

### National Cancer Institute

**Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)**

**Deadline:** 10/17/2019  

**About:** This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Michelle Mollica  
(240) 276-7621  
michelle.mollica@nih.gov

---

### National Cancer Institute

**Neural Regulation of Cancer (R01 Clinical Trial Not Allowed)**

**Deadline:** 10/21/2019  

**About:** This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system's contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Chamelli Jhappan  
(240) 276-6200  
jhappanc@mail.nih.gov

---

### National Cancer Institute

**NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)**

**Deadline:** 10/18/2019  

**About:** This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; innovative preclinical studies, including the use of new clinically-relevant models and imaging technologies, which could lead to first-in-human clinical trials, and therapeutic outcome disparities, including biomarkers or genetic/epigenetic signatures, among diverse racial/ethnic populations, including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines.

**Period of Support:** 2 years
Funds/Direct Costs: The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

Program Contact: William Timmer
(240) 276-6130
william.timmer@nih.gov

National Cancer Institute
Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)
Deadline: 11/12/2019

About: This Funding Opportunity Announcement (FOA) invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium. Goals of the SCLC Consortium pertinent to this FOA are: 1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity; 2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations; and 3) to understand clinical resistance to drug and radiation therapy and its rapid development.

Period of Support: 5 years
Funds/Direct Costs: Budgets are limited to $450,000 Direct Costs (excluding consortium F&A costs) per year.

Program Contact: Suzanne Forry
(240) 276-5922
forryscs@mail.nih.gov

Request for Applications (RFA)

National Cancer Institute
Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)
Deadline: 10/18/2019

About: This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.

Period of Support: Up to 3 years
Funds/Direct Costs: Applicants may request a maximum of $800,000 direct costs per year

Program Contact: Tiffany Wallace
(240) 276-5114
wallaceti@mail.nih.gov

National Cancer Institute
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
Deadline: 11/20/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

Period of Support: Up to 2 years
Funds/Direct Costs: Direct costs are limited to $275,000 over a two year period. No more than $200,000 may be requested in a single year.

Program Contact: Juli Klemm
(301) 480-5778
juli.klemm@nih.gov

National Cancer Institute
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
Deadline: 11/20/2019

About: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

Period of Support: Up to 3 years
Funds/Direct Costs: Direct costs are limited to $300,000 per year

Program Contact: Juli Klemm
(301) 480-5778
juli.klemm@nih.gov
Multiple Institutes, including the National Cancer Institute

HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)

**Deadline:** 10/22/2019


**About:** The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $500,000 direct cost per year.

**Program Contact:** Diane St. Germain

(240) 276-7082
dstgermain@mail.nih.gov

National Cancer Institute

Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)

**Deadline:** 11/12/2019


**About:** This R21 NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of pain target discovery and validation projects. These studies may involve considerable risk but may lead to a breakthrough in a pain treatment.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the two-year project period may not exceed $275,000.

**Program Contact:** Ann O’Mara

(240) 276-7050
omaraa@mail.nih.gov

Multiple Institutes, including the National Cancer Institute

Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not Allowed)

**Deadline:** 11/12/2019


**About:** The purpose of this Funding Opportunity is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain.

**Period of Support:** Up to 3 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed $500,000 direct cost per year.

**Program Contact:** Diane St. Germain

(240) 276-7082
dstgermain@mail.nih.gov

Multiple Institutes, including the National Cancer Institute

Biomarker for Pain (R61/R33 Clinical Trial Optional)

**Deadline:** 11/25/2019


**About:** The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the validation of strong candidate biomarkers and endpoints for breakthrough in a pain treatment.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** Application budgets may not exceed $100,000 in direct costs per year.

**Program Contact:** Juli Klemm

(301) 480-5778
juli.klemm@mail.nih.gov

National Cancer Institute

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

**Deadline:** 11/20/2019


**About:** The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Direct costs are limited to $600,000 per year

**Program Contact:** Juli Klemm

(301) 480-5778
juli.klemm@mail.nih.gov
pain that can be used to facilitate the development of non-opioid pain therapeutics from discovery through Phase II clinical trials.

**Period of Support:** Up to 5 years

**Funds/Direct Costs:** Application budgets are not limited but need to reflect the actual needs of the proposed project.

**Program Contact:** Ann O'Mara
(301) 496-8541
omaraa@mail.nih.gov

---

**Multiple Institutes, including the National Cancer Institute**

**Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research (R21 Clinical Trial Not Allowed)**

**Deadline:** 10/8/2019


**About:** The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute’s (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals.

**Period of Support:** Up to 2 years

**Funds/Direct Costs:** The combined budget for direct costs for the entire project period may not exceed $275,000.

**Program Contact:** Mutema Nyankale
(240) 276-5987
nyankalem@nih.gov

---

**Intramural Funding Opportunities**

**Massey Cancer Center**

**American Cancer Society Institutional Research Grants**

**Deadline:** 10/18/2019

[https://www.massey.vcu.edu/research/funding/acs-institutional-research-grants/](https://www.massey.vcu.edu/research/funding/acs-institutional-research-grants/)

**About:** Grant applications are now being invited from junior faculty for the award of small research grants of up to $30,000 for one year to perform basic, pre-clinical, clinical and cancer-control research studies (including but not limited to health services, psychosocial/behavioral, epidemiologic and health policy/outcome cancer research).

The American Cancer Society Institutional Research Grants (ACS-IRG) are awarded to junior faculty to pursue basic, pre-clinical, clinical and cancer-control research studies. These grants are intended for new investigators who are within six years of their first academic appointment. *NEW: Special Interest Award in Cancer Health Equity Research: ACS IRG will fund one Special Interest Award per year to support projects in areas of cancer health equity and disparities research.

**Period of Support:** 1 year

**Funds/Direct Costs:** Up to $30,000

**Program Contact:** Georgia Stratton
(804) 628-1594
stratongs@vcu.edu